Is Celgene Corporation (NASDAQ:CELG) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. The top picks of these firms have historically outperformed the market when we account for known risk factors, making them very valuable investment ideas.
Is Celgene Corporation (NASDAQ:CELG) a cheap investment today? The smart money is betting on the stock. The number of long hedge fund positions advanced by 4 in recent months. Celgene Corporation (NASDAQ:CELG) was in 62 hedge funds’ portfolios at the end of the third quarter of 2015. There were 58 hedge funds in our database with Celgene Corporation (NASDAQ:CELG) holdings at the end of the previous quarter. At the end of this article, we will also compare Celgene Corporation (NASDAQ:CELG) to other stocks, including Mitsubishi UFJ Financial Group Inc (ADR) (NYSE:MTU), QUALCOMM, Inc. (NASDAQ:QCOM), and Starbucks Corporation (NASDAQ:SBUX) to get a better sense of its popularity.
At the moment, there are many methods shareholders use to assess publicly traded companies. A pair of the most underrated methods are hedge fund and insider trading activity. Our experts have shown that, historically, those who follow the top picks of the top hedge fund managers can trounce the market by a significant amount (see the details here).
With all of this in mind, we’re going to view the latest action regarding Celgene Corporation (NASDAQ:CELG).
What does the smart money think about Celgene Corporation (NASDAQ:CELG)?
At the end of Q3, a total of 62 of the hedge funds tracked by Insider Monkey were bullish on this stock, an increase of 7% from one quarter earlier. With hedge funds’ sentiment swirling, there exists a few noteworthy hedge fund managers who were increasing their holdings substantially (or already accumulated large positions).
According to Insider Monkey’s hedge fund database, Samuel Isaly’s OrbiMed Advisors has the largest position in Celgene Corporation (NASDAQ:CELG), worth close to $388.7 million, corresponding to 3.9% of its total 13F portfolio. Coming in second is Alkeon Capital Management, managed by Panayotis Takis Sparaggis, which holds a $209.3 million position; the fund has 4.4% of its 13F portfolio invested in the stock. Some other peers that hold long positions consist of Cliff Asness’ AQR Capital Management, Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital, and Jerome Pfund and Michael Sjostrom’s Sectoral Asset Management.